Several biotech names posted notable after-hours gains on Tuesday, driven by clinical trial updates, fresh funding announcements, and upcoming product showcases. From gene editing breakthroughs to Alzheimer's trial enrollment, here's a quick look at the latest movers and what's ahead for each.Shares of Prime Medicine Inc. (PRME) rose 8.14% in after-hours trading on Tuesday, reaching $5.05 after closing the regular session up 16.46$4.67. The stock traded between $3.96 and$4.70 during the day, with a 5 ...